{"id":141477,"date":"2026-08-06T15:26:20","date_gmt":"2026-08-06T15:26:20","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/141477\/"},"modified":"2026-08-06T15:26:20","modified_gmt":"2026-08-06T15:26:20","slug":"novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons-5","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/141477\/","title":{"rendered":"Novo Nordisk A\/S: Trading in Novo Nordisk shares by board members, executives and associated persons"},"content":{"rendered":"

\"Novo<\/a> Novo Nordisk A\/S <\/p>\n

Bagsv\u00e6rd, Denmark, 6 August 2026\u00a0\u2014 This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596\/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

D\u00c9SIR\u00c8E JANTZEN ASGREEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Member of the Board of Directors <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

ELISABETH DAHL CHRISTENSEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Member of the Board of Directors <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

METTE B\u00d8JER JENSEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Member of the Board of Directors <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

Story Continues <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

SEMSI KILIC MADSEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Member of the Board of Directors <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

EMIL KONGSH\u00d8J LARSEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, International Operations <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

KARSTEN MUNK KNUDSEN <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, Chief Financial Officer (CFO) <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

KASPER B\u00d8DKER MEJLVANG <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, Global Manufacturing & Supply <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

MAZIAR MIKE DOUSTDAR <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

President and CEO <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

MARTIN HOLST LANGE <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, R&D and Chief Scientific Officer (CSO) <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

THILDE GYNTHE B\u00d8GEBJERG KR\u00d8YER <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, Enterprise IT & Quality <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

1 <\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated <\/p>\n

a) <\/p>\n

Name of the Board member\/Executive\/Associated Person <\/p>\n

TANIA SABROE <\/p>\n

2 <\/p>\n

Reason for the notification <\/p>\n

a) <\/p>\n

Position\/status <\/p>\n

Executive Vice President, People, Organisation & Corporate Affairs <\/p>\n

b) <\/p>\n

Initial notification\/Amendment <\/p>\n

Initial notification <\/p>\n

3 <\/p>\n

Details of the issuer <\/p>\n

a) <\/p>\n

Name <\/p>\n

Novo Nordisk A\/S <\/p>\n

b) <\/p>\n

LEI <\/p>\n

549300DAQ1CVT6CXN342 <\/p>\n

4 <\/p>\n

Details of the transaction(s) <\/p>\n

a) <\/p>\n

Description of the financial instrument,
type of instrument, <\/p>\n

Shares<\/p>\n

\u00a0 <\/p>\n

Identification code <\/p>\n

Novo Nordisk B DK0062498333 <\/p>\n

b) <\/p>\n

Nature of the transaction <\/p>\n

Other transaction (vesting of shares in
accordance with Restricted Shares programme \u2013 Novo Nordisk 100th Anniversary Shares) <\/p>\n

c) <\/p>\n

Price(s) and volume(s) <\/p>\n

Price(s) <\/p>\n

Volume(s) <\/p>\n

DKK 294.30 <\/p>\n

74 <\/p>\n

d) <\/p>\n

Aggregated information <\/p>\n

\u00a0<\/p>\n

74 shares
DKK 21,778.20 <\/p>\n

e) <\/p>\n

Date of the transaction <\/p>\n

2026-08-05 <\/p>\n

f) <\/p>\n

Place of the transaction <\/p>\n

Outside a trading venue <\/p>\n

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,<\/a> Facebook<\/a>, Instagram<\/a>, X<\/a>, LinkedIn<\/a> and YouTube<\/a>. <\/p>\n

Contacts for further information <\/p>\n

Company announcement No 49 \/ 2026 <\/p>\n

Attachment <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S Bagsv\u00e6rd, Denmark, 6 August 2026\u00a0\u2014 This company announcement discloses the data of the transaction(s) made…\n","protected":false},"author":2,"featured_media":141478,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[526,525,272,67731,527],"class_list":["post-141477","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-financial-instrument","tag-initial-notification","tag-novo-nordisk","tag-restricted-shares","tag-transaction"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117049267789835293","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/141477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=141477"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/141477\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/141478"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=141477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=141477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=141477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}